Navigation Links
Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm
Date:6/16/2008

Transaction reinforces Deloitte's leading position in the life sciences

industry

NEW YORK, June 16 /PRNewswire/ -- Deloitte has announced today an agreement to acquire Recombinant Capital, Inc. (Recap), a leading life sciences subscription database and advisory services firm. Included in the acquisition is Recap's unique database that provides more than 1,500 subscribers with access to over 20 years of historical data used to track significant publicly available information in the life sciences industry, ranging from alliance formations to intellectual property ownership and clinical trials data.

Deloitte's life sciences consulting practice was ranked number one by Kennedy Information in 2007 in terms of revenue and market share. Deloitte will further reinforce its market leadership position with the acquisition of Recap. The transaction also extends Deloitte's portfolio of services to include subscription database services, further complementing the consulting, financial advisory, tax, audit and enterprise risk services currently offered to life sciences clients. The addition of Recap's services will enhance Deloitte's litigation support, M&A, licensing and valuation capabilities.

"New business models are emerging that require life sciences companies to consider new strategies for growth, including forging alliances, entering emerging markets, executing mergers and acquisitions and developing new types of drugs," said Terry Hisey, vice chairman and US industry leader for Deloitte LLP's Life Sciences industry group. "With the addition of Recombinant Capital, Deloitte will be uniquely positioned to provide clients with unparalleled access to information and analyses critical to management in their development of future growth plans."

"The choice to integrate Recombinant Capital and Deloitte merges Recap's unique strategic data with Deloitte's scale, scope of services and client base, creating a powerful combination," said Mark Edwards, founder and managing director of Recombinant Capital. "Our clients will benefit from Deloitte's proven industry track record, and our people will benefit from the opportunity to continue to develop their careers with one of the world's leading professional services firms."

Recap's customers include approximately 90 percent of the top-tier biotech and pharmaceutical companies by market capitalization. The company also serves as a supplier of data to organizations, including venture capital firms, major law firms, universities and medical centers.

The acquisition is expected to be completed within the next month. Financial terms of the transaction have not been disclosed.

About Deloitte

As used in this document, "Deloitte" means one or more subsidiaries of Deloitte LLP. Please see http://www.deloitte.com/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

About Recombinant Capital

Recombinant Capital (Recap) is a San Francisco Bay Area-based subscription database and advisory services firm. Recap's mission is to ensure availability of adequate resources for biotechnology enterprises by providing comprehensive and timely advice and analysis related to the environment for corporate and product development and alliance formation. Recap's clients include biotechnology and pharmaceutical companies, plus several universities, investment banking and venture firms active in the biotechnology area.

Marykate Reese

Public Relations

Deloitte

+1 203-257-0452

mareese@deloitte.com


'/>"/>
SOURCE Deloitte
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Deloitte Leadership Offers Crucial Convergence Considerations for Life Sciences Companies
2. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Align Technology, Inc. Ranked 23rd in Deloittes Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies
6. Alma Lasers Ranked 9th in Deloitte Technology Fast 50 Award
7. Deloitte Chairman of the Board Sharon L. Allen Named Chairman of the American Friends of the Phelophepa Train
8. China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor
9. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
10. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
11. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... Microbial genomics leader ... grant award has been made to Dr. Renato Polimanti of Yale University School ... the oral microbiome. Grant proposals have been vetted by the company’s scientific review ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation ... and lumbar disc production, company President, Jake Lubinski will be traveling to Switzerland ... AxioMed disc in Bern, Lucerne, and Zurich to discuss the benefits of a ...
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... ) today announced the submission of a Marketing Authorization Application ... a biosimilar candidate to Avastin ® (bevacizumab). The companies ... to the EMA. "The submission of ABP ... seeks to expand our oncology portfolio," said Sean E. ...
(Date:12/2/2016)... ... 01, 2016 , ... ACEA Biosciences, Inc. announced today that it will be ... at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December ... clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring the ...
Breaking Biology Technology:
(Date:11/15/2016)... Research and Markets has announced the addition of the ... their offering. ... The global bioinformatics market ... 6.21 Billion in 2016, growing at a CAGR of 21.1% during ... is driven by the growing demand for nucleic acid and protein ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
Breaking Biology News(10 mins):